Arrowstreet Capital
ASMB icon

Arrowstreet Capital’s Assembly Biosciences ASMB Stock Holding History

Arrowstreet Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Buy
39,446
+1,634
+4% +$46.6K ﹤0.01% 1538
2025
Q4 		$1.29M Buy
+37,812
New +$1.22M ﹤0.01% 1503

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Arrowstreet Capital's ASMB Position: Q1 2026 in Review

Arrowstreet Capital increased its Assembly Biosciences (ASMB) stake by 4.3% in Q1 2026, buying an estimated $46.6K and bringing the position to 39,446 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Arrowstreet Capital first reported a position in ASMB in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.29M in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Arrowstreet Capital held 39,446 shares of Assembly Biosciences worth $1.09M as of Q1 2026.
  • Arrowstreet Capital bought 1,634 Assembly Biosciences shares in Q1 2026, an estimated $46.6K.
  • Assembly Biosciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1538 holding.
  • Arrowstreet Capital first reported a position in Assembly Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Arrowstreet Capital's Assembly Biosciences position peaked at $1.29M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.